FDA Brief

Warning letters Drugs

FDA warning letter to

Shantou Qiwei Industry Co., LTD

High riskIssued Jun 2Posted Jun 9Center for Drug Evaluation and Research (CDER)

FDA warns Shantou Qiwei, a Chinese OTC drug maker, that it never tested talc for asbestos, making its products adulterated.

What happened

FDA did not inspect the plant. It reviewed records the company sent after FDA's August 14, 2025 request under section 704(a)(4) of the FD&C Act, which lets FDA demand records from a registered drug facility. The records showed the company does not test its talc-containing ingredients for identity, does not test talc for asbestos, and does not validate the test results it accepts from suppliers; FDA says the company's methods fall short of Current Good Manufacturing Practice (CGMP), the basic quality rules for making drugs.

What FDA found

  1. The company did not test incoming ingredients, including talc, to confirm identity, purity, strength and quality before using them.

    21 CFR 211.84(d)(1) and (d)(2)
  2. The company did not test its talc for asbestos, a known cancer-causing mineral that can occur naturally with talc and can be inhaled from the finished product.

    21 CFR 211.84(d)(1) and (d)(2)
  3. The company accepted supplier certificates of analysis without first checking, and periodically rechecking, that the supplier's test results are reliable.

    21 CFR 211.84(d)(2)
  4. The quality control unit approved talc for manufacturing even though its written specifications had no asbestos test and no tests for assay and several impurities.

    21 CFR 211.22 and 21 CFR 211.160(b)
  5. The company's talc specifications fall short of the current USP talc monograph, which drugs with USP-recognized ingredients are generally required to meet.

    Section 501(b) of the FD&C Act

What FDA wants

FDA tells the company to correct the violations promptly and reply in writing within 15 working days describing the fixes and how it will prevent recurrence. The letter also requires asbestos testing of retained talc lots, or of finished batches if no retain exists, within 30 calendar days, plus a risk assessment of in-date products and action such as customer notifications or recalls for contaminated lots.

Who should pay attention

  • brands that buy talc-containing OTC drugs from this contract manufacturer
  • US importers and retailers selling OTC drug products made in China
  • talc suppliers and labs doing asbestos testing for drug makers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Curia New York, Inc.

    FDA warned Curia New York's Rensselaer, New York API plant that undocumented lab injections, shredded records and shared passwords violate CGMP.

    High risk
  2. Gopaldas Visram & Co., Ltd.

    FDA warns Indian OTC drug maker Gopaldas Visram over talc asbestos testing and data integrity failures.

    High risk
  3. Laboratorios Dr. Collado S.A.

    FDA warns Laboratorios Dr. Collado over inadequate asbestos testing and quality oversight for talc-containing over-the-counter drugs.

    High risk
  4. Revlon Group Holdings, LLC

    FDA cited Revlon's Oxford, NC over-the-counter drug plant for failing to test talc for asbestos and weak quality oversight.

    High risk